Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Traumacel is a sterile, absorbable hemostatic agent composed of oxidized cellulose, specifically the calcium salt of plant-derived polysaccharides. It is utilized in various surgical and outpatient settings to control capillary, venous, and small arterial bleeding, particularly when conventional hemostatic methods are insufficient. The product line includes multiple formulations such as Traumacel PULVIS (powder), Traumacel FAM (nonwoven fabric), and Traumacel TAF (net), allowing for application in classical, robotic, and endoscopic surgeries. Beyond its primary mechanical hemostatic action—forming a coagulum upon contact with blood—Traumacel exhibits bactericidal properties and has been shown to stimulate fibroblast metabolic activity, which may enhance the healing process in both acute surgical wounds and chronic ulcers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxidized cellulose.